Thus, a better understanding of how DAM responds to amyloid-β and tau accumulation, respectively, will not only help to determine when and how TREM2 agonistic antibodies should be administered to AD patients but will also be important for further elucidating the pathogenic mechanisms of AD. This evidence concerns the gene TREM2 and Alzheimer disease.